Literature DB >> 27168666

High-Yield Birth-Cohort Hepatitis C Virus Screening and Linkage to Care Among Underserved African Americans, Atlanta, Georgia, 2012-2013.

Lesley S Miller1, Francois Rollin1, Shelly-Ann Fluker1, Kristina L Lundberg1, Brandi Park1, Kristi Quairoli2, Nyiramugisha K Niyibizi3, Anne C Spaulding3.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) infection disproportionately affects certain populations, including those born between 1945 and 1965 (i.e., baby boomers) and African Americans. As part of the Hepatitis Testing and Linkage to Care initiative, which promoted hepatitis B and hepatitis C screening, posttest counseling, and linkage to care at 34 U.S. sites, we conducted routine HCV screening to identify previously undiagnosed, primarily African American baby boomers with chronic hepatitis C infection and link them to care.
METHODS: We launched the Internal Medicine Trainees Identifying and Linking to Treatment for Hepatitis C (TILT-C) initiative at the Grady Memorial Hospital Primary Care Center and Grady Liver Clinic in Atlanta, Georgia, in October 2012, and present results from the first year. TILT-C faculty implemented an electronic medical record prompt and conducted educational sessions to boost HCV screening. A project coordinator tracked testing outcomes and linked HCV-positive patients to care.
RESULTS: Of 2,894 patients tested for anti-HCV, 201 (6.9%) tested positive. Men had a significantly higher (p<0.001) prevalence of HCV infection than women, with 106 of 1,091 (9.7%) men compared with 95 of 1,803 (5.3%) women testing anti-HCV positive. A total of 174 of 201 (86.6%) anti-HCV-positive patients received HCV ribonucleic acid (RNA) testing. Of 124 patients with a positive HCV RNA test, 122 were referred to care and 120 attended the first appointment.
CONCLUSION: The TILT-C screening program was feasible and effective in detecting previously undiagnosed HCV infection and linking patients to care. The unexpectedly high prevalence of HCV infection in this primarily African American, baby boomer population underscores the need for aggressive HCV screening efforts in similar populations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27168666      PMCID: PMC4853333          DOI: 10.1177/00333549161310S213

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  19 in total

1.  Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence.

Authors:  Philip R Spradling; Loralee Rupp; Anne C Moorman; Mei Lu; Eyasu H Teshale; Stuart C Gordon; Cynthia Nakasato; Joseph A Boscarino; Emily M Henkle; David R Nerenz; Maxine M Denniston; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2012-08-08       Impact factor: 9.079

2.  Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic.

Authors:  Lesley Miller; Shelly-Ann Fluker; Melissa Osborn; Xiaoxia Liu; Akilah Strawder
Journal:  J Natl Med Assoc       Date:  2012 May-Jun       Impact factor: 1.798

3.  Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-09-03       Impact factor: 25.391

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

5.  Physician nonadherence with a hepatitis C screening program.

Authors:  William N Southern; Mari-Lynn Drainoni; Bryce D Smith; Elisa Koppelman; M Diane McKee; Cindy L Christiansen; Allen L Gifford; Cindy M Weinbaum; Alain H Litwin
Journal:  Qual Manag Health Care       Date:  2014 Jan-Mar       Impact factor: 0.926

6.  Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; John W Ward
Journal:  Ann Intern Med       Date:  2012-12-04       Impact factor: 25.391

7.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

Review 8.  The effects of on-screen, point of care computer reminders on processes and outcomes of care.

Authors:  Kaveh G Shojania; Alison Jennings; Alain Mayhew; Craig R Ramsay; Martin P Eccles; Jeremy Grimshaw
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  Hepatitis C screening trends in a large integrated health system.

Authors:  Benjamin P Linas; Haihong Hu; Devra M Barter; Michael Horberg
Journal:  Am J Med       Date:  2014-01-28       Impact factor: 5.928

10.  Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Authors:  Homie Razavi; Antoine C Elkhoury; Elamin Elbasha; Chris Estes; Ken Pasini; Thierry Poynard; Ritesh Kumar
Journal:  Hepatology       Date:  2013-05-06       Impact factor: 17.425

View more
  9 in total

1.  Increasing Hepatitis C Screening in a Federally Qualified Health Center: A Quality Improvement Initiative.

Authors:  Melissa D Klein; Bryna J Harrington; Joan East; Jennifer Cunningham; Nicole Ifill; Jan Lee Santos
Journal:  J Healthc Qual       Date:  2021 Sep-Oct 01       Impact factor: 1.095

2.  Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era.

Authors:  Sarah C Dupont; Shelly-Ann Fluker; Kristi M Quairoli; Cameron Body; Ike Okosun; Jennifer Lom; Lesley S Miller
Journal:  Public Health Rep       Date:  2019-11-22       Impact factor: 2.792

3.  Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus.

Authors:  Sammy Saab; Timothy Ahn; Terina McDaniel; Beshoy Yanny; Myron J Tong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-08

4.  Characteristics and Specialist Linkage to Care of Patients Diagnosed With Chronic Hepatitis C Across Different Settings in an Urban Academic Hospital: Implications for Improving Diagnosis and Linkage to Care.

Authors:  Dan C S Im; Susheel Reddy; Claudia Hawkins; Shannon Galvin
Journal:  Front Microbiol       Date:  2021-02-11       Impact factor: 5.640

5.  Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.

Authors:  Alexander G Geboy; Whitney L Nichols; Stephen J Fernandez; Sameer Desale; Peter Basch; Dawn A Fishbein
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

6.  Hepatitis C Screening: Barriers to Linkage to Care.

Authors:  Sammy Saab; Youssef P Challita; Lisa M Najarian; Rong Guo; Satvir S Saggi; Gina Choi
Journal:  J Clin Transl Hepatol       Date:  2019-04-12

7.  Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic.

Authors:  Smita Bakhai; Naren Nallapeta; Mohammad El-Atoum; Tenzin Arya; Jessica L Reynolds
Journal:  BMJ Open Qual       Date:  2019-09-29

8.  Differences in inpatient and outpatient hepatitis C virus prevalence and linkage to care rates in a safety net hospital hepatitis C screening program.

Authors:  Hima Veeramachaneni; Brandi Park; Danielle Blakely; Andres Palacio; Rapheisha Darby; Shelly-Ann Fluker; Robert H Lyles; Lesley S Miller
Journal:  J Gastroenterol Hepatol       Date:  2021-03-31       Impact factor: 4.369

9.  Routine Screening and Linkage to Care for Hepatitis C Virus in an Urban Safety-Net Health System, 2017-2019.

Authors:  Bijou R Hunt; Christopher Ahmed; Kimberly Ramirez-Mercado; Christopher Patron; Nancy R Glick
Journal:  Public Health Rep       Date:  2020-11-11       Impact factor: 2.792

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.